[Expression patterns of non-viral transfection with GFP in the organ of Corti in vitro and in vivo. Gene therapy of the inner ear with non-viral vectors].

HNO
M PraetoriusH Staecker

Abstract

Diseases of the inner ear such as presbycusis, tinnitus, sudden hearing loss, and vertigo affect many patients, but so far there are no specific therapy options. Gene therapy might become a potential modality of treatment. Viral vectors are standard in animal models to date. Future considerations, however, call for a further evaluation of non-viral transfection methods. The non-viral transfection agents Metafectene, Superfect, Effectene, and Mirus TransIT were incubated with a plasmid coding for GFP. In vivo, the plasmid-agent mix was injected via the membrane of the round window, and 48 h later the inner ear was perfused, harvested, decalcified, and histologically evaluated for GFP expression. Cationic lipids (Metafectene) and dendrimers (Superfect) were able to transfect cells in the area of the organ of Corti and lead to GFP expression. The polyamine (Mirus TransIT) did show expression of GFP in the area of Rosenthal's canal and in the area of the inner hair cell. The combination of a non-liposomal lipid with a DNA condensing component (Effectene) did not show transfection of the organ of Corti. In the area of the spiral ganglia cells, GFP expression was seen with all the transfection agents. Non-viral transfection agents ar...Continue Reading

References

Oct 1, 1988·The Journal of Cell Biology·S I DworetzkyC M Feldherr
Jun 1, 1995·Current Opinion in Cell Biology·F Melchior, L Gerace
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·J F Kukowska-LatalloJ R Baker
Mar 29, 1996·Neuroscience Letters·Y RaphaelB J Roessler
Jul 23, 1998·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·H StaeckerT R Van De Water
May 15, 2001·Acta Oto-laryngologica·H StaeckerT R Van De Water
Aug 23, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·C L Gebhart, A V Kabanov
May 16, 2002·Bioconjugate Chemistry·Omayra L Padilla De JesúsFrancis C Szoka
Jul 23, 2002·Biological & Pharmaceutical Bulletin·Eriko UchidaTakao Hayakawa
Aug 29, 2003·The Journal of Biological Chemistry·N D SonawaneA S Verkman
Oct 18, 2003·ORL; Journal for Oto-rhino-laryngology and Its Related Specialties·Mark PraetoriusHinrich Staecker
Oct 31, 2003·Expert Reviews in Molecular Medicine·Alan L ParkerPaul J Sheridan
Oct 11, 2005·Drug Discovery Today·Munna M Vio, Ralph H Holme
Oct 11, 2005·Drug Discovery Today·Alec N Salt, Stefan K R Plontke
Mar 26, 2008·Gene Therapy·S Akhtar

❮ Previous
Next ❯

Citations

Sep 18, 2008·Current Opinion in Otolaryngology & Head and Neck Surgery·Mohamed Hamid, Dennis Trune
Nov 18, 2009·Biochemistry. Biokhimii︠a︡·D G ShcharbinM Bryszewska
Feb 20, 2014·HNO·H A Breinbauer, M Praetorius
Oct 31, 2013·Expert Opinion on Drug Delivery·Dzmitry ShcharbinMaria Bryszewska
Sep 15, 2012·Experimental and Therapeutic Medicine·Hui WangShan-Kai Yin
May 30, 2013·Molecular Medicine Reports·Li Xia, Shankai Yin
Aug 18, 2017·Journal of the Association for Research in Otolaryngology : JARO·Hena AhmedJeffrey R Holt

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.